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EDITORIAL REVIEW
Racial differences in the incidence and progression of
renal diseases
Recent studies in the United States have demonstrated a
higher incidence of end—stage renal disease (ESRD) treatment
among Blacks, Mexican Americans, and Native Americans
than amor4g Whites [1—111. There are at least two potential
factors thdt may contribute to the observed differences: 1) the
prevalence of the underlying diseases that cause ESRD may be
higher in non-Whites than in Whites (a disease-specific model);
and 2) regardless of basic etiology, Blacks may develop ESRD
more often or more rapidly than Whites (a race-specific model).
Race-specific differences may be genetic or, in the broadest
sense, environmental and therefore potentially remediable. The
basic question is whether or not race/ethnic background is an
independent risk factor for developing ESRD in the United
States. This review summarizes the differential rates of ESRD
treatment in the U.S. analyzed according to underlying disease
for Blacks, Whites and, where data are available, Mexican
Americans and Native Americans. We will emphasize studies
which assess incidence of ESRD among those known to have an
identifiable underlying disease. Because the higher prevalence
of hypertension in Blacks is frequently cited as responsible for
causing or accelerating progressive renal disease, we will also
examine the data that are available regarding racial differences
in the effect of blood pressure on the development and progres-
sion of renal disease. The purpose is to examine more critically
the hypothesis that the higher incidence of ESRD treatment in
Blacks can be accounted for by the higher prevalence of
hypertension.
As shown in Figure 1, the incidence of ESRD treatment has
increased over the period from 1982 to 1988, with a three- to
fourfold higher rate in Blacks than Whites. Easterling [1] and
Rostand et a! [2] first brought attention to the high rates of
ESRD among Blacks. The data from these and subsequent
studies are shown for diabetes mellitus in Table 1, glomerulo-
nephritis in Table 2, polycystic kidney disease in Table 3, and
hypertension in Table 4. All of these studies rely on the
classification of underlying cause reported by each patient's
nephrologist. Criteria for these determinations have not been
standardized and renal histology is often not a part of the
available clinical data. Thus, these aggregate data may be
influenced by prevailing perceptions of the frequency with
which a particular disease leads to ESRD. The United States
Renal Data Service (USRDS) data [10] and those presented by
Eggers, Connerton and McMullan [41 represent Medicare-
eligible patients only, excluding up to 10% of the ESRD
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population. Importantly, essentially all data reviewed here and
elsewhere are based on patients referred for treatment of ESRD
(dialysis or transplantation) and thus are highly influenced by
changes in the patterns of referral over the past 10 years. These
data also underestimate the true incidence of ESRD as not all
patients with ESRD are appropriate for treatment and thus are
not referred. Despite these considerations, the racial pattern in
ESRD treatment is remarkably consistent.
End-stage renal disease from diabetes mellitus
Table 1 shows that the reported incidence ratio for ESRD
from diabetes ranges from 2.9 to 5.6for Blacks versus Whites,
with a significant racial difference in each study in which
statistical testing has been applied. Some of this racial pattern is
expected on the basis of the higher prevalence of diabetes in
Blacks than in Whites. Based on the National Health Interview
Survey (NHIS) for 1979 to 1981 [12], the prevalence of diabetes
is 1.35-fold higher in Blacks than Whites, with the highest
differences at ages greater than 45 years.
Cowie et al [9] addressed the question of whether there is
excess ESRD from diabetes in Blacks after accounting for their
increased prevalence of diabetes. They used the Michigan
Kidney Registry data from 1974 to 1983 to determine ESRD
incidence secondary to diabetes, and the NHIS in combination
with the 1980 Michigan Census to determine prevalence of
diabetes. The average annual incidence of ESRD was 127.8 per
100,000 Black diabetic patients versus 50.2 per 100,000 White
diabetic patients, yielding an incidence ratio of 2.55 (95% C.I.
2.26,2.64). When strict criteria for distinguishing Type I from
Type II diabetes were applied in a geographical subset of the
population, the racial incidence ratio was 1.03 (0.73,1.33) for
Type I and 4.31 (3.36,5.25) for Type II diabetes. Thus the
excess ESRD in Blacks with diabetes relates to factors that
have a demonstrable effect largely if not selectively on Type II
disease but not on Type I disease. These same data project that
5.82% of Type I diabetic patients would progress to ESRD over
a 10 year period versus 0.5% for Type II diabetes [9].
In a similar study, Stephens et al [11] used incidence data
from ESRD Network 17 (Kentucky and Southwestern Ohio) in
combination with diabetes prevalence rates from the NHIS and
the 1980 census to determine the incidence of ESRD in the
diabetic population analyzed by race. They too made an at-
tempt to distinguish Type I from Type II diabetes, using a
community-based survey. The Black-to-White incidence ratio
was 2.96 (1.79:4.88) for Type I and 4.86 (3.65:6.47) for Type II
diabetes. Thus, both studies [9, 11] which took prevalence and
type of diabetes into account, show excess risk for Blacks with
diabetes, with the racial difference greater for Type II disease.
Diabetic Mexican Americans also have excess risk of ESRD.
From the Texas Kidney Health Program database, Pugh et a! [7]
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Fig. 1. Incidence of end-stage renal disease
treatment in the United States 1982—1 988, by
race. Symbols are: (D) Black; (•) Native
1 American/Alaskan Native; (D) Asian/Pacific
1989 Islander, () White. Data are from the USRDS
[10].
Table 1. Annual incidence of treatment for ESRD attributed to diabetes per 100,000 general population
Author Location Years
Black White .Incidence ratio
Black/Whitecases/lOO,000
Easterling [1] Southeast Michigan 1973—75 1.50 0.46 3.3
Sugimoto et al [3] Eastern U.S. 1973—79 — — M2/F3
Rostand et al [2] Jefferson Co., AL 1974—78 1.5 0.45 3.4
Eggers et al [4] U.S. 1980 4.0 1.4 2.9
Weller et a! [5] Michigan 1974—81 3.0 0.8 3.8
Cowie et al [9] Michigan 1974—83 6.2 1.4 4.4
Pugh et at [7J Texas 1978—84 5.66 1.33 4.3
Stephens et al [11] SW Ohio and Kentucky 1983—84 9.25 1.74 5.3












USRDS [101" U.S. 1986—88 11.51 3.16 3.6
Abbreviation USRDS is United States Renal Disease Service.
a Age adjustedb Age and sex adjusted
determined that the age-adjusted diabetic ESRD incidence ratio
for Mexican Americans versus non-Hispanic Whites over the
period 1978 to 1984 was 4.5 to 6.6. Based on previously
published data indicating a threefold higher prevalence of
diabetes in Mexican Americans versus non-Hispanic Whites
[13, 14], there appears to be excess ESRD from diabetes which
cannot be accounted for solely by the difference in diabetes
prevalence. Analysis of age-specific incidence of ESRD showed
highest relative risk for Mexican Americans versus non-His-
panic Whites at ages greater than 40 years, suggesting again that
Type II diabetes is responsible for the excess [7].
Diabetic nephropathy is endemic among many tribes of
Native Americans [15, 16]. The Navajo, the largest tribe, are
almost 10 times more likely to develop ESRD from diabetes
than the aggregate U.S. population. Data taking into account
the high prevalence of diabetes in the Native American popu-
lation are not available and thus it is not clear that diabetes is
more nephropathic in Native Americans than in similarly af-
fected populations.
There are thus compelling data that Blacks with diabetes
progress to ESRD more frequently than Whites with diabetes.
Mexican and Native Americans also have higher rates of ESRD
from diabetes than Whites, though data taking into account the
high prevalence of diabetes among these groups are lacking.
Although patients with Type I diabetes develop ESRD more
often than patients with Type II diabetes, the racial difference in
the number of ESRD patients is predominantly from Type II
diabetes, which is much more prevalent than Type I among
Blacks.
End-stage renal disease from glomerulonephritis
Table 2 shows the incidence of treated ESRD from glomeru-
lonephritis in several studies analyzed by race. Although the
rates are again higher for Blacks than for Whites, prevalence
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Table 2. Annual incidence of treatment for ESRD attributed to glomerulonephritis per 100,000 general population
Black White Incidence ratio
Author Location Years cases/100,000 Black/White
Easterling [1] Southeast Michigan 1973—75 3.38 1.24 2.7
Sugimoto et al [3] Eastern U.S. 1973—79 — — 1.5
Rostand et al [2] Jefferson Co., AL 1974—78 2.2 0.68 3.3
Eggers et al [4] U.S. 1980 2.6 1.4 1.9
Weller et alES] Michigan 1974—81 2.4 1.4 1.7
Pugh et al [7] Texas 1978—84 2.91 1.12 2.6
Ferguson et al [61 Los Angeles 1980—85 3.2 0.96 3.3
USRDS [10]" U.S. 1984 3.84 1.53 2.5
USRDS [10]" U.S. 1986—88 3.96 1.64 2.4
Abbreviation USRDS is United States Renal Disease Service.
a Age adjusted
b Age and sex adjusted
Table 3. Annual incidence of treatment for ESRD attributed to polycystic kidney disease per 100,000 general population
Black White Incidence ratio
Author Location Years cases/100,000 Black/White
Easterling [1] Southeast Michigan 1973—75 0.21 0.31 0.7
Sugimoto et al [31 Eastern U.S. 1973—79 — — 0.5
Rostand et al [2] Jefferson Co., AL 1974—78 0.28 0.36 0.8
Eggers et al [4] U.S. 1980 0.3 0.5 0.6
Ferguson et al [6] Los Angeles 1980—85 0.35 0.17 2.1
USRDS [10] U.S. 1984 0.52 0.44 1.2
USRDS [l0] U.S. 1986-88 0.50 0.49 1.0
Abbreviation USRDS is United States Renal Disease Service.
a Age and sex adjusted
data by race for the various diseases grouped into this category
are not available. Specifically, there exist no reliable data on
racial differences in either the prevalence of renal disease or
incidence of ESRD from lupus, focal segmental glomeruloscle-
rosis, membranous nephropathy, membranoproliferative gb-
merulonephritis, or renal disease associated with systemic
vasculitis. Moreover, the data in Table 2 are apt to involve a
significant problem with misclassification since the criteria for
designating the etiology of ESRD as glomerulonephritis are
neither simple nor standardized.
A few studies provide fragmentary information in this area.
Among those patients having a renal biopsy, IgA nephropathy
is a more common diagnosis in Whites than Blacks [17, 18].
This may reflect a racial difference in gene frequency rather
than a difference in the susceptibility of the kidney to injury.
For idiopathic nephrotic syndrome, no racial differences in
disease behavior, response to therapy, or influence of hyper-
tension on the clinical course were found in a retrospective
analysis from the Collaborative Study of Adult Glomerular
Disease [19]. One report suggests that lupus nephritis may
progress to ESRD more often in Black and Hispanic children
than in White children [201. There is some evidence that focal
glomerulosclerosis associated with either intravenous heroin or
human immunodeficiency virus may affect non-Whites at risk
more often than Whites at similar risk. Heroin-associated
nephropathy is a clinical syndrome of proteinuria and renal
insufficiency in the setting of intravenous heroin use, most often
diagnosed in Black men [21]. It is unclear whether this repre-
sents a true racial difference in susceptibility to progression, or
instead, an artifact of diagnostic, sampling, or reporting biases.
The case for a true racial difference is stronger for HIV-
associated nephropathy, a similar syndrome with mainly focal
glomerulosclerosis on biopsy [22, 23]. Most of the reported
cases of HIV-associated nephropathy have been in Blacks
[22—241. Even when intravenous drug abusers are excluded,
there are 10 times more Blacks than Whites with HIV-associ-
ated nephropathy reported in the literature, despite the much
greater White population at risk [24, 25]. Nevertheless, it seems
unlikely that heroin and HIV-associated renal disease could
account for all of the racial disparity indicated in Table 2.
Prospective cohort studies are needed to determine which
specific forms of glomerulonephritis are responsible.
End-stage renal disease from polycystic kidney disease
As shown in Table 3, the incidence of ESRD attributed to
polycystic kidney disease (PKD) is comparable for Whites and
Blacks. Moreover, the incidence rates for ESRD attributed to
cystic kidney diseases (predominantly PKD) have remained
stable over time, probably reflecting a low rate of misclassifi-
cation (Fig. 2 and the discussion of misclassification below).
Because the autosomal dominant form of polycystic kidney
disease (ADPKD) is a genetic disease which can be reliably
diagnosed in conjunction with ultrasonography and without
renal biopsy, misclassification is probably less common than
with other leading causes of ESRD. Unfortunately, accurate
prevalence data by race for polycystic kidney disease are
lacking, making the racial distribution of the at-risk population
unclear. Information on racial differences in the prevalence of
Fig. 2. New cases of end-stage renal disease
treatment in the United States 1980—1988, by
_________
underlying etiology. Data are from the
1 USRDS [10]. Symbols are: () diabetes
1989 mellitus, (•) hypertension; ()
glomerulonephritis; (0) PKD.
Table 4. Annual incidence of treatment for ESRD attributed to hypertension per 100,000 general population
Author Location Years
Black White .Incidence ratio
Black/Whitecases/l00,000
Easterling [1] Southeast Michigan 1973—75 5.94 0.35 17.0
Sugimoto et at [3] Eastern U.S. 1973—79 — — M7/F6
Rostand et al [2] Jefferson Co., AL 1974—78 6.4 0,36 17.7
Eggers et at [4] U.S. 1980 7.9 1.2 6.6
Weller et a! [5] Michigan 1974—81 7.6 0.7 10.9
McClellan et a! [8] Georgia 1979—83 10.2 1.2 8.4
Pugh et al [7] Texas 1978—84 11.8 1.1 10.9
Ferguson et at [6] Los Angeles 1980—85 11.1 2.5 4.4
USRDS [10]b U.S. 1984 12.53 1.64 7.6
USRDS [lO]' U.S. 1986—88 14.62 2.24 6.5
Abbreviation USRDS is United States Renal Disease Service.
a Age-adjustedb Age and sex adjusted
ADPKD and its progression to ESRD would be especially
useful in discerning a race-specific difference in susceptibility to
renal injury. Also, the ADPKD model provides an opportunity
to examine the contribution that concomitant hypertension
might have on the rate of progression to ESRD. In essence, the
absence of a clear racial pattern in the incidence of ESRD
attributed to ADPKD argues against the hypothesis that all
forms of renal disease are more aggressive in Blacks, whether
because of concomitant hypertension or not. This conclusion,
however, is highly dependent on the uncertain assumptions that
the gene frequency for ADPKD is equal in Blacks and Whites
and that diagnostic renal ultrasonography is performed with
comparable frequency in Blacks and Whites. Race-specific
information on the occurrence and progression of ADPKD
needs to be acquired.
End-stage renal disease from hypertension
A racial difference is most striking for ESRD attributed to
hypertension, with a 4.4- to 17.7-fold higher incidence in Blacks
than Whites (Table 4). The prevalence of hypertension (defined
as systolic blood pressure greater than 140 mm Hg, diastolic
blood pressure greater than 90 mm Hg, or current antihyper-
tensive drug therapy) is 1.3 times higher in Blacks than in
Whites [26], but not high enough as a primary factor to account
for the markedly higher incidence of ESRD from hypertension
in Blacks (Table 2). McClellan, Tuttle and Issa [8] determined
the age and sex adjusted incidence rates of ESRD from hyper-
tension in Georgia for 1979 to 1983 using incident cases as the
numerator and a population-based estimate of the prevalence of
hypertension as the denominator. The rate was 204 per 100,000
for Blacks versus 35.5 per 100,000 in Whites, yielding an
incidence ratio of 5.7. Thus, there is an excess rate of progres-
sion to ESRD among blacks with hypertension that is not
explained by differences in age or sex distribution, or by the
higher prevalence of hypertension in the black population.
Likewise, there is a higher incidence of ESRD from hyperten-
sion among Mexican Americans than non-Hispanic Whites,
despite a similar or lower prevalence of hypertension [7].
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The problem of misclassification
Some of the ESRD attributed to hypertension was probably
caused by undiagnosed vascular or renal parenchymal diseases
with secondary hypertension. There should thus be concern
about the frequency of etiologic misclassification of ESRD and
whether there are racial or historical differences in misclassifi-
cation as perceptions change. For example, Figure 2 shows the
annual incidence of treated ESRD by reported underlying
etiology. Most notably, the annual incidence of ESRD attrib-
uted to cystic kidney disease, perhaps the most easily and
objectively defined form, is stable; this incidence presumably
reflects mainly the genetic frequency, unaffected by changes in
diagnostic sensitivity or therapy. In contrast, the annual inci-
dence of ESRD attributed to diabetes has increased dramati-
cally and can perhaps be explained by the trend during this
period for wider application of ESRD treatment modalities to
older and less healthy diabetic patients. That is, the treatment
opportunities changed rather than the true incidence of the
disease. The basis for the increased annual incidence of ESRD
attributed to hypertension is less clear, however. The preva-
lence of elevated blood pressure decreased between NHANES
I (1971 to 1975) and NHANES 11(1976 to 1980), due to
treatment of a larger proportion of the hypertensive population
[27]. Moreover, the incidences of non-renal complications of
hypertension such as stroke and cardiovascular disease have
been declining dramatically since 1960 [28]. Thus, there is
concern that the increased attribution of ESRD to hypertension
may reflect shifts over time in perceptions about etiologies or in
diligence in establishing primary diagnoses. Nonetheless, the
available data indicate that Blacks and other non-White groups
have a higher incidence of ESRD attributed to hypertension
compared to Whites.
Because hypertension is more prevalent and more severe in
Blacks, it is often assumed that this is the reason that ESRD
incidence rates are higher in Blacks than Whites. The implicit
assumptions are: (1) hypertension causes renal insufficiency
and/or (2) effective blood pressure control prevents or slows the
progression of established renal insufficiency.
What is the incidence of renal insufficiency secondary to
hypertension?
The development of overt renal insufficiency in patients with
uncomplicated hypertension is relatively rare. Whelton and
KIag [29] recently reviewed in detail the existing data on
hypertension as a risk factor for the development of renal
disease. Clearly in the era preceding the widespread use of
potent antihypertensive medications and dialysis/transplanta-
tion, malignant hypertension was associated with a high rate of
renal morbidity and mortality which improved after pharmaco-
logic therapy was applied [30—32]. It has been more difficult to
establish that lesser degrees of hypertension cause renal insuf-
ficiency. Data from randomized placebo-controlled trials of
treatment in mild and moderate hypertension have yielded only
suggestive evidence that treatment lowers the incidence of renal
complications, in contrast to its marked effectiveness on car-
diovascular complications [29]. In the Veterans Administration
Cooperative Study of 380 patients with diastolic blood pressure
at entry of 90 to 114 mm Hg, only two patients in the placebo
group (none in the active treatment group) developed a serum
creatinine concentration > 2 mg/dl and only one patient in the
placebo group (none in the active treatment group) developed
qualitative proteinuria over a mean follow-up period of over
three years [33]. Even among the 143 patients with diastolic
blood pressures between 115 and 129 mm Hg, only two patients
in the placebo group (none in the active treatment group) had to
be withdrawn from the study because of renal insufficiency [32].
Conceivably renal insufficiency may be a relatively late com-
plication of hypertension, or one of such low incidence relative
to cardiovascular complications that much larger and longer
trials would be required to show clear benefit in reducing the
incidence of renal insufficiency. We are unlikely to acquire this
information from randomized controlled trials, as it would now
be unethical to perform a clinical trial that allowed some
patients to have poor blood pressure control for an extended
period of time, given the established benefits of antihyperten-
sive therapy in reducing the risk of stroke and congestive heart
failure [32, 34]. The Hypertension Detection and Follow-up
Program (HDFP) [35] provides an estimate of the incidence of
renal insufficiency among patients under treatment for hyper-
tension. A racially mixed population of almost 11,000 patients
were randomized to either "stepped-care" at one of the study
centers or "referred-care" by their usual care provider. About
6% of the study population had at least 1 + qualitative protein-
uria and about 5% had serum creatinines (Cr) > 1.5 mg/dl at
baseline. In a secondary analysis [36], the development after
five years of a Cr  2 mg/dl and 1.25 times the baseline value
was used as the indicator of deterioration of glomerular filtra-
tion rate. Of the 8683 participants (both groups) for whom data
were available, 200 (2.3%) met the criteria at five years of
follow-up. Of those with baseline Cr < 1.5 mg/dl, 110 of 8268
(1.3%) met the criteria versus 90 of 415(21.7%) with baseline Cr
1.5. These data suggest that only about 1.3% of patients with
treated hypertension may develop clinically detectable renal
insufficiency over five years, and that about 22% of those with
clinical renal disease at the outset will progress with treatment.
We can use the HDFP data to estimate the total number of
patients with hypertension who will develop new onset renal
insufficiency defined by serum creatinine values. Based on
NHANES II data, there were 30 to 35 million people in the U.S.
in 1976 to 1980 with hypertension [26]. HDFP data suggest an
annual incidence of hypertensive renal disease of 0.26% (1.3%/s
years). Combining these statistics results in a projected 78,000
to 91,000 patients with new-onset renal insufficiency from
hypertension per year. To account for the 2310 observed new
cases of ESRD attributed to hypertension in 1980 (Fig. 2), only
3 to 4% of these patients would have had to eventually progress
to ESRD. Thus, despite the low rate of incident renal disease
from hypertension, because hypertension is so prevalent, even
a trickle of patients (about l/10000 hypertensive patients per
year in this hypothetical scenario) would lead to the numbers of
patients developing ESRD attributed to hypertension that we
are now experiencing. One implication of this analysis is that
any study designed specifically to address the question of
whether or not treatment of essential hypertension diminishes
the incidence of chronic renal disease would require a nearly
prohibitive number of patients for an extended period of time.
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Does effective blood pressure control slow the progression of
established renal insufficiency?
An association between blood pressure and the pace of
progression of established renal insufficiency of any cause is
reasonably well established. During the feasibility phase of the
Modification of Diet in Renal Disease (MDRD) study, the rate
of loss of GFR function was inversely correlated with mean
arterial blood pressure, including values in the traditionally
normal range [37]. In a retrospective study of patients who
eventually developed ESRD, the decline in reciprocal Cr over
time was steeper during periods of poorer blood pressure
control [381. That this is a causal relationship is suggested by a
prospective trial of patients with renal insufficiency attributed
to hypertension in whom blood pressure was aggressively
controlled and non-creatinine measurements of GFR were
made over three years of follow-up [39]. Strict blood pressure
control stabilized or improved renal function in more than half
their patients (16 of 22). This ongoing randomized trial and the
MDRD study may yield important information regarding appro-
priate blood pressure goals in patients with established renal
insufficiency.
Are racial differences in rates of end-stage renal disease
related to poorer blood pressure control among non-whites?
In the HDFP, Blacks were significantly more likely than
Whites to develop an increased Cr [361, but fewer Blacks than
Whites achieved blood pressure goals [351. The HDFP thus
leaves open the possibility that poorer blood pressure control
rather than other race-related factors accounts for the racial
difference in the incidence of ESRD.
Though no other prospective studies have examined the role
of race directly, three retrospective analyses supply some
information. Rostand et a! [401 determined the frequency of a
rise in Cr of 0.4 mg/dl among patients with essential hyperten-
sion and baseline Cr < 1.5 mgldl followed for at least 12
months. Of 94 such patients followed for a mean of more than
50 months, 14 (14.8%) met this criterion for presumed decline in
renal function. Some of these patients had a low Cr at baseline
and their increase by 0.4 mg/dl may simply reflect regression to
the mean. Nevertheless, stepwise regression analysis indicated
that Black race, older age, a higher number of missed office
visits, and employment as a laborer were all associated with a
rise in Cr. Blood pressure control was not significantly associ-
ated with the rise in Cr.
Brazy and Fitzwilliam [41] reported a retrospective analysis
of data from 200 patients with progressive renal insufficiency as
defined by a greater than 20% decrease in reciprocal Cr over at
least six months. Fifty-six percent of the patients were Black
and 98% were male. Multivariable regression analysis indicated
that diastolic blood pressure, type of antihypertensive medica-
tion, and age were significant predictors of the reciprocal Cr
versus time slope, but race and primary diagnosis were not.
Unlike the study of Rostand et al [40] which focused on newly
detected increases in Cr, the patients in this study were selected
to have established and progressive renal disease, perhaps
accounting for the different results.
Using a computerized database, Tierney, McDonald and Luft
[42] analyzed data from 6880 hypertensive patients followed for
at least 12 months. Seventy-two percent of this group were
Black and 41% had diabetes. Most of the diabetic patients (95%)
had Type II disease. The number of patients developing a Cr
equal to or greater than 2.0 mg/dl was determined. This crite-
rion was met by 18.1% of patients over the period of follow-up
which averaged 5.2 years. Multivariable regression analysis
indicated that older age, Black race, higher treated systolic
blood pressure, presence of diabetes, and presence of heart
failure were all independent predictors for the development of a
Cr of 2.0 mg/dl. After other relevant variables were taken into
account, Blacks had a 1.9-fold greater incidence of renal
insufficiency than Whites. When Cr was treated as a continuous
variable in the regression model, treated systolic blood pres-
sure, presence of diabetes, and Black race were the only
independent predictors. Thus, the study with the largest base
population and most patients with incident renal disease [42]
indicates that both blood pressure control and race are impor-
tant predictors of progression, while one smaller study did not
find blood pressure control to be an independent predictor [40].
On the basis of the available data it seems likely that, even after
accounting for differences in blood pressure control, Black
patients are more likely to develop renal disease than Whites.
Possibilities for racial differences in the incidence of ESRD
It is reasonable to conclude from the above analysis that
racial/ethnic differences exist in the incidence of ESRD treat-
ment in the U.S., but it seems premature to attribute these
differences simply to the higher prevalence of hypertension in
Blacks. Other race-related factors that are genetic or environ-
mental may be involved in either the incidence or progression of
renal disease, or both. Many have been discussed previously
including racial differences in access to medical care, the
susceptibility of the kidney to injury from hypertension [43],
differences in renal vascular resistance [44, 45], plasma renin
activity [46, 47], diurnal variation of sodium excretion [48],
urinary kallikrein [49], catecholamine responsiveness [50], ion
transporters (Na,K-ATPase, Na-Li exchange) [51, 52],
dietary potassium [53] and racial/ethnic differences in the role of
insulin in linking obesity, glucose intolerance, hypertension,
and vascular disease [54, 55]. Discussion of the significance of
these findings is beyond the scope of this review. Data regard-
ing gene-determined racial differences of potential pathophysi-
ologic relevance in renal disease other than hypertension are
lacking.
Summary
There is an excess incidence of ESRD treatment among
non-White North Americans that is not completely explained
by the racial prevalences of the underlying diseases, including
hypertension, which can potentially cause renal disease. The
racial difference is particularly striking for presumed nephro-
sclerosis from hypertension and for nephropathy from Type II
diabetes, but is not yet substantiated for ESRD attributed to
polycystic kidney disease or Type I diabetes. The existing data
are insufficient to support the notion that poorer blood pressure
control alone is responsible for the racial differences in incident
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ESRD. Black race (and possibly Mexican or Native American
heritage) may be a specific risk factor for ESRD, independent of
hypertension and its treatment.
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